This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Sep 7;142(10):861-862.

doi: 10.1182/blood.2023021050.

Pembrolizumab: a key for some, but not all, HL

Affiliations

PMID: 37676693
DOI: 10.1182/blood.2023021050

Free article

Editorial

Pembrolizumab: a key for some, but not all, HL

Chan Y Cheah. Blood. 2023.

Free article

. 2023 Sep 7;142(10):861-862.

doi: 10.1182/blood.2023021050.

Author

Affiliation

¹ Sir Charles Gairdner Hospital and University of Western Australia.

PMID: 37676693
DOI: 10.1182/blood.2023021050

No abstract available

PubMed Disclaimer

Comment on

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH. Armand P, et al. Blood. 2023 Sep 7;142(10):878-886. doi: 10.1182/blood.2022019386. Blood. 2023. PMID: 37319435 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Medical
- MedlinePlus Health Information